Search Results
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 27, 2026, 09:00 ET Azenta, Inc. (AZTA) Securities Fraud Investigation - Levi & Korsinsky
eligible to participate in the AZTA investigation?A: Investors who purchased AZTA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.Q: What do AZTA investors need to do right
More news about: Levi & Korsinsky, LLP
May 21, 2026, 16:05 ET Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
BURLINGTON, Mass., May 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued progress against its key
More news about: Azenta
May 21, 2026, 15:33 ET INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Azenta, Inc. - AZTA
May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 20, 2026, 09:00 ET AZTA Investor Alert: Levi & Korsinsky Investigates Azenta, Inc. (AZTA) for Potential Securities Fraud
to participate in the AZTA investigation? A: Investors who purchased AZTA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares. Q: What do AZTA investors need to do right
More news about: Levi & Korsinsky, LLP
May 14, 2026, 20:15 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 13, 2026, 09:00 ET Azenta, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Azenta, Inc. (AZTA)
professionals. Hundreds of millions recovered.Frequently Asked Questions About the AZTA Investigation Q: Who is eligible to participate in the AZTA investigation? A: Investors who purchased AZTA stock or securities and suffered financial losses may be eligible. Eligibility is based
More news about: Levi & Korsinsky, LLP
May 05, 2026, 16:30 ET Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
intact.BURLINGTON, Mass., May 5, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2026.
More news about: Azenta
Apr 29, 2026, 16:06 ET Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the market opens.The Company
More news about: Azenta
Apr 07, 2026, 08:15 ET Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead
More news about: Azenta
Mar 04, 2026, 09:11 ET Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a
More news about: Azenta
Feb 24, 2026, 16:05 ET Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March
More news about: Azenta
Feb 09, 2026, 16:05 ET Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific
More news about: Azenta
Feb 04, 2026, 06:30 ET Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025.
More news about: Azenta
Jan 21, 2026, 16:05 ET Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.The
More news about: Azenta
Dec 29, 2025, 08:00 ET Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L.
BURLINGTON, Mass., Dec. 29, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA
More news about: Azenta
Dec 10, 2025, 12:43 ET Azenta Authorizes $250 Million Share Repurchase Program
BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its
More news about: Azenta
Nov 21, 2025, 06:30 ET Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025
pointsBURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025.
More news about: Azenta
Nov 12, 2025, 16:05 ET Azenta Announces Fiscal 2025 Fourth Quarter and Full Year Conference Call and Webcast
BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens.
More news about: Azenta
Nov 04, 2025, 16:05 ET Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer
BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection
More news about: Azenta
Oct 15, 2025, 08:00 ET Azenta to Host Investor Day at its Biorepository Facility in Indianapolis, Indiana
BURLINGTON, Mass., Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana.
More news about: Azenta
Aug 05, 2025, 06:30 ET Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance
BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.
More news about: Azenta
Jul 31, 2025, 16:05 ET Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology
BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine
More news about: Azenta
Jul 31, 2025, 08:30 ET Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care
www.nephronomics.com. About Azenta Life Sciences:Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and
More news about: Fresenius Medical Care Holdings, Inc.